Clinical trial · Interventional
Clinical Significance of Supraclavicular Lymph Node Dissection for Breast Cancer
A Multicenter, Randomised, Open-label Prospective Clinical Trial to Evaluate the Clinical Significance of Supraclavicular Lymph Node Dissection for Breast Cancer Patients With Ipsilateral Supraclavicular Lymph Node Metastasis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer patients with ipsilateral supraclavicular lymph node metastasis are defined as Ⅲc stage (N3) according to the newly published 8th AJCC TNM staging system. No concret guide line was supported to such patients. It is still pending whether to exert supraclavicular lymph node dissection to breast cancer patients with ipsilateral supraclavicular lymph node metastasis. To evaluate the clinical significance and complication of supraclavicular lymph node dissection for breast cancer patients with ipsilateral supraclavicular lymph node metastasis, the investigators randomize patients into two groups, one group is supraclavicular lymph node dissection with radiotherapy group, the other group is radiotherapy group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Stage III | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| supraclavicular area radiotherapy | Radiation | — | UNRESOLVED |
| supraclavicular lymph node dissection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- supraclavicular lymph node dissection and raidiotherapy
- description
- breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular lymph node dissection and supraclavicular area radiotherapy
- interventionNames
- Procedure: supraclavicular lymph node dissection
- type
- ACTIVE_COMPARATOR
- label
- supraclavicular area radiotherapy
- description
- breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular area radiotherapy
- interventionNames
- Radiation: supraclavicular area radiotherapy
Primary outcomes (1)
- measure
- Disease free survival
Eligibility
Eligibility (as posted)
- Sex
- Female
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Ability to understand the study procedures and contents, and willingness to voluntarily sign the written informed consent form; 2. Age≤75 years old, female; 3. Histologically confirmed breast cancer; 4. Histologically or cytologically confirmed ipsilateral supraclavicular lymph node metastasis； 5. cT0-T3； 6. low and moderate risk for anesthesia Exclusion Criteria: 1. Absolute and relative contraindication for surgery or radiation； 2. existing distant metastasis before surgery； 3. non-invasive breast cancer； 4. with contralateral breast cancer； 5. Previous history of breast cancer or other malignancies； 6. ECOG≥2； 7. inflammatory breast cancer； 8. pregnancy； 9. any serious complications which caused patients not suitable to participate this study
References
Publications (0)
Data not yet available